Improve disease classification and guide therapy decisions

Melanoma accounts for just 1% of skin cancer diagnoses but causes the majority of skin cancer deaths.1 Because of the heterogeneity of melanoma and unique genetic features of the cancer, prognosis and treatment can vary greatly. Accurate classification of melanoma is vital to understanding both the illness’s implications on the patient and the best treatment plan.

Melanoma Test menu


Our MayoComplete melanoma panel uses next-generation sequencing to evaluate 17 melanoma-specific genes for variations related to diagnosis, prognosis, and tumor classification. Our team of board-certified geneticists and genetic counselors is available to assist with questions related to testing options and results interpretation.

Key testing


  • High accuracy and sensitivity.
  • Helps distinguish between benign and malignant cases.
  • Guides decisions on targeted treatment options. 
  • Developed, validated, analyzed, and interpreted by Mayo Clinic experts.
  • Evaluates BAP1, BRAF, CDKN2A, CTNNB1, EIF1AX, GNA11, GNAQ, HRAS, KIT, KRAS, MAP2K1, MAP2K2, NF1, NRAS, SF3B1, TERT-promoter, and TP53 genes.


  1. The American Cancer Society medical and editorial content team. Key Statistics for Melanoma Skin Cancer. American Cancer Society. Updated January 12, 2022. Accessed October 7, 2022.
  2. New genetic regions linked to risk of melanoma. NIH Research Matters, National Institutes of Health. Published May 5, 2020. Accessed October 7, 2022.

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.